GT Biopharma, Inc. (GTBP)
Full history for every metric is available with a Kvantra account
No price history available.
Key financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | 0 | 0 | 0 | 0 | 0 | 0 | 0 | - |
| Operating profit | $m | -12 | -16 | ||||||
| Net profit | $m | -28 | -58 | -21 | -8 | -13 | -28 | -22 | - |
| EPS reported | $ | -6.25 | -104.0 | ||||||
| Operating cashflow per share | $ | -58.56 | -0.37 | ||||||
| Capex per share | $ | 0.00 | 0.00 | ||||||
| FCF per share | $ | -58.56 | -0.37 | ||||||
| Free cash flow | $m | -13 | -14 | ||||||
| Net debt | $m | -7 | -5 | ||||||
| Book value equity | $m | 6 | 4 | ||||||
| Book value per share | $ | 1.05 | 2.30 | ||||||
| Number of shares | m | 5.51 | 1.55 | ||||||
| DPS (TTM paid) | $ | 0.04 | 0.15 |
Financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E TTM | x | - | - | ||||||
| P/B LTM | x | 0.75 | 1.21 | ||||||
| P/S LTM | x | 0.00 | 0.00 | ||||||
| P/FCF LTM | x | -0.34 | -0.30 | ||||||
| EV/EBITDA LTM | x | 0.09 | 0.12 | ||||||
| EV/Sales LTM | x | 0.00 | 0.00 | ||||||
| Earnings Yield LTM | % | -6.55% | -1.93% | ||||||
| FCF Yield | % | -298.31% | -333.24% | ||||||
| Quality | |||||||||
| ROE | % | -489.96% | -444.56% | ||||||
| ROIC | % | -2.15% | -5.96% | ||||||
| Operating margin | % | 0.00% | 0.00% | ||||||
| Gross margin | % | 0.00% | 0.00% | ||||||
| FCF/Sales | % | - | - | ||||||
| Growth and momentum | |||||||||
| EPS Growth YoY | % | - | - | ||||||
| Sales Growth YoY | % | - | - | ||||||
| Net Income Growth YoY | % | - | - | ||||||
| FCF Growth | % | - | - | ||||||
| Operating Profit Growth | % | - | - | ||||||
| Dividend and capital structure | |||||||||
| Dividend Yield | % | +5.29% | 0.00% | ||||||
| Dividend Growth | % | - | - | ||||||
| Payout Ratio | % | -0.66% | -0.28% | ||||||
| FCF/Debt | x | - | - | ||||||
| Net Debt/EBITDA | x | 0.24 | 0.24 | ||||||
| EBIT/Net interest | x | -97.81 | 16,337.00 | ||||||
| Net debt/market cap | % | 0.00% | 0.00% | ||||||
| Net debt/Equity | x | -1.18 | -1.39 | ||||||
| Gross debt/equity | x | 0.00 | 0.00 | ||||||
Price target estimates
Based on consensus from external analysts. Not Kvantra's opinion.
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
ESG
| Metric | 2024 | 2025 | 2026 |
|---|---|---|---|
| ESG-score | |||
| Environmental score | |||
| Social score | |||
| Governance score | |||
| Risk rating |
Company overview
GT Biopharma, Inc. is a biopharmaceutical company in the clinical development phase, dedicated to discovering and bringing to market novel immuno-oncology treatments. Their innovative approach centers on a proprietary technology platform called Tri-specific Killer Engager (TriKE) fusion proteins, which are designed to harness the body's immune cells. Central to their pipeline is GTB-3550, a single-chain tri-specific recombinant fusion protein conjugate currently undergoing Phase I/II clinical trials. This therapeutic candidate is being evaluated for its potential in treating myelodysplastic syndromes, acute myeloid leukemia that has relapsed or proven refractory to prior treatments, advanced systemic mastocytosis, and other malignancies expressing CD33. The company's research also includes GTB-3650, which is in preclinical development targeting CD33 on myeloid leukemias, and GTB-5550, another preclinical asset aimed at solid tumors that are positive for B7-H3. GT Biopharma has forged key collaborations, including a co-development agreement with Altor BioScience Corporation for the clinical advancement of a 161533 TriKE fusion protein for various cancer indications. Furthermore, they maintain a license agreement with the Regents of the University of Minnesota to develop and commercialize cancer therapies utilizing their TriKE technology. Founded in 1965, the company previously operated as OXIS International, Inc. before rebranding to GT Biopharma, Inc. in July 2017. Its corporate operations are based in Brisbane, California.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
No price history available.
Consensus from external analysts. Not Kvantra's opinion.
Based on consensus from external analysts. Not Kvantra's opinion.
GT Biopharma, Inc. is a biopharmaceutical company in the clinical development phase, dedicated to discovering and bringing to market novel immuno-oncology treatments. Their innovative approach centers on a proprietary technology platform called Tri-specific Killer Engager (TriKE) fusion proteins, which are designed to harness the body's immune cells. Central to their pipeline is GTB-3550, a single-chain tri-specific recombinant fusion protein conjugate currently undergoing Phase I/II clinical trials. This therapeutic candidate is being evaluated for its potential in treating myelodysplastic syndromes, acute myeloid leukemia that has relapsed or proven refractory to prior treatments, advanced systemic mastocytosis, and other malignancies expressing CD33. The company's research also includes GTB-3650, which is in preclinical development targeting CD33 on myeloid leukemias, and GTB-5550, another preclinical asset aimed at solid tumors that are positive for B7-H3. GT Biopharma has forged key collaborations, including a co-development agreement with Altor BioScience Corporation for the clinical advancement of a 161533 TriKE fusion protein for various cancer indications. Furthermore, they maintain a license agreement with the Regents of the University of Minnesota to develop and commercialize cancer therapies utilizing their TriKE technology. Founded in 1965, the company previously operated as OXIS International, Inc. before rebranding to GT Biopharma, Inc. in July 2017. Its corporate operations are based in Brisbane, California.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free